NCI-2024-09213

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-Label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the treatment of Selected HER2-mutated or Overexpressed/ Amplified Solid Tumours

The Beamion PANTUMOR-1 study is a Phase 2, multicenter, open-label clinical trial designed to test a new oral drug called Zongertinib (BI 1810631) in people with solid tumors that have HER2 mutations or HER2 overexpression/amplification. HER2 (human epidermal growth factor receptor 2) is a protein that can cause cancer cells to grow and divide rapidly when present in high amounts or when altered by mutations. While HER2-targeted treatments already exist for some cancers like breast or gastric cancer, many other tumor types with HER2 changes do not yet have effective options. The main goals are to determine how well Zongertinib works at shrinking or controlling tumors, how long the responses last, and what side effects occur.

Phase 2: An advanced point of testing, where they're trying to confirm if a treatment works well.

Mutations: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06581432

Clinical Trial Site: Sinai

To see all available clinical trials click here.